Skip to main content

This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

bioRxiv logoLink to bioRxiv
[Preprint]. 2023 Mar 17:2023.01.25.525462. Originally published 2023 Jan 25. [Version 2] doi: 10.1101/2023.01.25.525462

Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker

Martin S Taylor, Wu Connie, Peter C Fridy, Stephanie J Zhang, Yasmeen Senussi, Justina C Wolters, Wen-Chih Cheng, John Heaps, Bryant D Miller, Kei Mori, Limor Cohen, Hua Jiang, Kelly R Molloy, Bryanna L Norden, Brian T Chait, Michael Goggins, Irun Bhan, Joseph W Franses, Xiaoyu Yang, Mary-Ellen Taplin, Xinan Wang, David C Christiani, Bruce E Johnson, Matthew Meyerson, Ravindra Uppaluri, Ann Marie Egloff, Elyssa N Denault, Laura M Spring, Tian-Li Wang, Ie-Ming Shih, Euihye Jung, Kshitij S Arora, Lawrence R Zukerberg, Osman H Yilmaz, Gary Chi, Ursula A Matulonis, Yuhui Song, Linda Nieman, Aparna R Parikh, Matthew Strickland, Ryan B Corcoran, Tomas Mustelin, George Eng, Ömer H Yilmaz, Steven J Skates, Bo R Rueda, Ronny Drapkin, Samuel J Klempner, Vikram Deshpande, David T Ting, Michael P Rout, John LaCava, David R Walt, Kathleen H Burns
PMCID: PMC9900799  PMID: 36747644

Abstract

Improved biomarkers are needed for early cancer detection, risk stratification, treatment selection, and monitoring treatment response. While proteins can be useful blood-based biomarkers, many have limited sensitivity or specificity for these applications. Long INterspersed Element-1 (LINE-1, L1) open reading frame 1 protein (ORF1p) is a transposable element protein overexpressed in carcinomas and high-risk precursors during carcinogenesis with negligible detectable expression in corresponding normal tissues, suggesting ORF1p could be a highly specific cancer biomarker. To explore the potential of ORF1p as a blood-based biomarker, we engineered ultrasensitive digital immunoassays that detect mid-attomolar (10-17 M) ORF1p concentrations in patient plasma samples across multiple cancers with high specificity. Plasma ORF1p shows promise for early detection of ovarian cancer, improves diagnostic performance in a multi-analyte panel, and provides early therapeutic response monitoring in gastric and esophageal cancers. Together, these observations nominate ORF1p as a multi-cancer biomarker with potential utility for disease detection and monitoring.

Full Text

The Full Text of this preprint is available as a PDF (1.6 MB). The Web version will be available soon.


Articles from bioRxiv are provided here courtesy of Cold Spring Harbor Laboratory Preprints

RESOURCES